Belsomra vs Trazodone: How to Switch Between Them Safely

Why Patients Switch Between These Two Drugs

Most switches happen because of side effects, cost, or incomplete efficacy. Trazodone is the most-prescribed off-label sleep medication in the United States, with over 20 million prescriptions annually for insomnia despite limited randomized controlled trial data supporting that use [1]. Suvorexant (Belsomra) earned FDA approval in 2014 based on two Phase III trials enrolling over 2,000 patients [2], yet its high out-of-pocket cost drives many patients toward trazodone.

A 2017 analysis of Veterans Affairs pharmacy data found that trazodone was prescribed for sleep in 72% of cases where it was dispensed at doses of 50 to 150 mg, confirming its dominant role as a sleep aid rather than an antidepressant at those dosages [3]. Patients who experience morning sedation, orthostatic hypotension, or priapism risk with trazodone often consider suvorexant. Conversely, patients on suvorexant who develop next-day somnolence, sleep paralysis, or who lose insurance coverage may benefit from switching to trazodone [4]. The 2017 American Academy of Sleep Medicine (AASM) clinical practice guidelines recommend suvorexant for sleep-maintenance insomnia but do not recommend trazodone due to insufficient evidence, a distinction worth considering when choosing direction [5].

How the Two Mechanisms Differ

Understanding the pharmacology explains why switching is uncomplicated. Suvorexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the lateral hypothalamus, suppressing the wake-promoting orexin/hypocretin system rather than broadly sedating the brain [2]. This targeted mechanism produced statistically significant improvements in both sleep onset and sleep maintenance in the Herring et al. trial (N=1,021), with a 20-mg dose reducing wake-after-sleep-onset (WASO) by 22.4 minutes versus placebo at month 3 [2].

Trazodone at sub-antidepressant doses (25 to 100 mg) works primarily through antagonism of serotonin 5-HT2A receptors and histamine H1 receptors, producing sedation without the GABAergic mechanism that characterizes benzodiazepines and Z-drugs [6]. A Cochrane-style systematic review by Mendelson (2005) concluded that trazodone data for insomnia were limited to small, short-duration studies and that efficacy beyond the first two weeks was not well-established [1].

Because suvorexant and trazodone act on entirely separate neurotransmitter systems (orexin vs. serotonin/histamine), stopping one and starting the other does not create overlapping withdrawal or rebound through the same pathway [7]. This is fundamentally different from switching between two GABAergic agents, where cross-tolerance and rebound anxiety are real concerns [8].

Switching from Trazodone to Belsomra (Suvorexant)

The transition from trazodone to suvorexant is the simpler direction. Trazodone at insomnia doses (25 to 100 mg) does not produce physical dependence requiring a taper, and its 5-to-9-hour half-life means it clears within 24 to 36 hours [6]. A patient can take their last trazodone dose one evening and begin suvorexant 10 mg the following night.

The FDA-approved starting dose for suvorexant is 10 mg taken within 30 minutes of bedtime, with at least 7 hours of planned sleep remaining [4]. The dose may be increased to 20 mg if 10 mg is tolerated but insufficient. Starting at 20 mg without a trial of 10 mg is discouraged by the prescribing information because higher doses correlate with increased next-day impairment [4].

One clinical nuance: patients who were using trazodone partly for its antidepressant properties at higher doses (150 to 300 mg) should not abruptly stop without discussing mood management with their prescriber. At antidepressant doses, trazodone discontinuation can trigger a serotonin-discontinuation syndrome with dizziness, nausea, and irritability [9]. The switch protocol below applies only to sub-antidepressant insomnia dosing.

A 2020 real-world study from Japan examining insomnia medication switching patterns found that patients transitioning from sedating antidepressants to orexin antagonists reported improved subjective sleep quality at 4 weeks, with particular gains in reducing early-morning awakenings [10]. Patients should expect suvorexant's full effect to develop over 7 to 14 nights, as the orexin system adapts to receptor blockade gradually [2].

Switching from Belsomra (Suvorexant) to Trazodone

This direction requires slightly more attention because of suvorexant's longer half-life. At 12 hours, a final 20-mg dose taken at 10 PM still produces meaningful OX2R occupancy through the following morning [11]. Starting trazodone (which adds H1 antagonism and alpha-1 blockade) on the same night could compound sedation and orthostatic risk, particularly in older adults [12].

The practical protocol: take the last suvorexant dose, skip one night of medication (the washout night), then begin trazodone 25 to 50 mg the following evening. Sleep quality on the washout night may be modestly reduced, but Phase III discontinuation data from the Herring et al. trial showed no statistically significant rebound insomnia after abrupt suvorexant cessation compared with placebo, including at the 40-mg dose (which exceeds the current maximum approved dose of 20 mg) [2].

An FDA review of suvorexant's abuse-potential studies confirmed that the drug produced minimal physical dependence signals in both preclinical and clinical evaluations, supporting the safety of abrupt discontinuation [13]. Trazodone can then be titrated from 25 mg upward in 25-mg increments every 3 to 5 nights based on response and tolerability, with most insomnia patients settling at 50 to 100 mg [1].

For patients over age 65, the American Geriatrics Society Beers Criteria flag both drugs for caution, though trazodone carries additional orthostatic hypotension risk that warrants blood pressure monitoring during the first week [14]. Starting trazodone at 25 mg in this population reduces fall risk while still providing clinically meaningful sedation through H1 receptor blockade [12].

Efficacy Comparison: What the Data Actually Show

No head-to-head randomized trial has compared suvorexant directly with trazodone. Clinicians must triangulate from separate study populations. The strongest suvorexant evidence comes from Herring et al. (2014), where 20 mg reduced subjective time to sleep onset (sTSO) by 8 minutes and WASO by 22 minutes versus placebo across 3 months in adults aged 18 and older [2]. A polysomnography sub-study confirmed objective improvements: latency to persistent sleep (LPS) decreased by 9 minutes and WASO by 29 minutes with 20 mg at month 1 [2].

Trazodone's evidence base is thinner. The most-cited trial, Walsh et al. (1998), studied 306 patients over only 2 weeks, finding that trazodone 50 mg improved subjective sleep versus placebo during week 1 but not week 2 [15]. Mendelson's 2005 review noted that "the evidence for trazodone's efficacy in primary insomnia is limited by the small number of studies, small sample sizes, and short treatment durations" [1]. A 2023 meta-analysis of low-dose trazodone for insomnia across 9 RCTs found a modest but statistically significant improvement in total sleep time (weighted mean difference: 18.3 minutes) and sleep quality scores, though heterogeneity was substantial [16].

The AASM 2017 guideline panel voted to recommend suvorexant for sleep-maintenance insomnia (weak recommendation, moderate evidence) while explicitly declining to recommend trazodone due to "very low quality evidence" [5]. This does not mean trazodone is ineffective for individual patients, but the evidence gap is real and should inform shared decision-making.

Side Effect Profiles That Drive the Switch

Side effects are the primary reason patients ask about switching. Suvorexant's Phase III safety data identified somnolence (7% vs. 3% placebo), headache, and abnormal dreams as the most common adverse events [2]. The FDA label includes a warning about complex sleep behaviors (sleep-walking, sleep-driving), though a post-marketing safety review found the incidence lower than with Z-drugs like zolpidem [4]. Sleep paralysis and hypnagogic hallucinations occurred in approximately 1% of patients, consistent with the drug's orexin-blocking mechanism mimicking features of narcolepsy [13].

Trazodone produces daytime sedation, dry mouth, dizziness, and orthostatic hypotension [6]. The serotonergic mechanism creates a small but clinically significant risk of priapism (estimated at 1 in 6,000 to 1 in 8,000 male patients), which the FDA considers serious enough to mandate a black-box-adjacent warning [6]. QTc prolongation has been reported at higher antidepressant doses but is not a major concern at the 25-to-100-mg insomnia range [17]. A retrospective cohort study of over 400,000 trazodone users found no significant increase in cardiac arrhythmias at doses below 150 mg daily [17].

Weight gain is negligible with suvorexant. Trazodone at insomnia doses also shows minimal weight effect, though at antidepressant doses (300+ mg) some patients report 2 to 4 kg gain over 6 months [6]. Neither drug carries the cognitive-impairment profile associated with long-term benzodiazepine use, making both reasonable options for patients transitioning off older sedative-hypnotics [8].

Drug Interactions to Check Before Switching

Suvorexant is metabolized by CYP3A4, meaning strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) significantly increase suvorexant exposure. The FDA label contraindicates suvorexant with strong CYP3A4 inhibitors and recommends a maximum of 10 mg with moderate inhibitors [4]. Trazodone is metabolized by CYP3A4 and to a lesser extent CYP2D6, so the same CYP3A4 inhibitors increase trazodone levels [6].

When switching from suvorexant to trazodone while on a moderate CYP3A4 inhibitor (diltiazem, erythromycin, fluconazole), start trazodone at 25 mg because clearance of both drugs will be impaired during the overlap window [18]. Trazodone also has additive serotonergic risk when combined with SSRIs, SNRIs, or tramadol, so patients on antidepressant therapy should have their serotonin-syndrome risk assessed before adding trazodone, even at low doses [9].

Suvorexant does not carry serotonergic risk. For patients on multiple serotonergic medications, this is a meaningful advantage favoring suvorexant over trazodone [4]. Alcohol potentiates both drugs and should be avoided within 4 hours of either medication [4][6].

Special Populations: Elderly, Hepatic Impairment, and Comorbid Depression

Older adults metabolize suvorexant more slowly, and the FDA recommends caution but does not mandate dose reduction [4]. In a dedicated elderly sub-study (age ≥65, N=423), suvorexant 15 mg and 30 mg improved WASO without excess falls versus placebo, though morning somnolence was more common [19]. For trazodone in the elderly, orthostatic hypotension and fall risk are the dominant concerns. A 2018 population-based study of nursing-home residents found trazodone associated with a 20% higher fall rate compared with non-users, though the rate was still lower than with benzodiazepines [14].

In hepatic impairment, suvorexant exposure increases modestly (AUC +27% in mild impairment) but requires no dose adjustment for mild-to-moderate disease [4]. Severe hepatic impairment is listed as a precaution. Trazodone similarly requires caution in liver disease, as reduced CYP3A4 activity can double plasma levels [6].

For patients with comorbid major depressive disorder, trazodone offers theoretical dual benefit: insomnia management at low dose with residual antidepressant activity. A 2014 study by Fagiolini et al. found that adding low-dose trazodone (75 to 150 mg) to SSRI therapy improved both insomnia severity and Hamilton Depression scores more than SSRI monotherapy [20]. Suvorexant has no antidepressant properties. If depression drives the insomnia, trazodone may be the more logical choice [5].

Cost and Insurance Considerations

Generic trazodone costs $4 to $10 per month at most pharmacies. Brand-name Belsomra lists at approximately $400 per month, and no generic suvorexant is yet available in the U.S. as of 2026 [4]. Many insurance formularies require prior authorization for suvorexant and may mandate a trial-and-failure of trazodone or a Z-drug first. The 2020 Institute for Clinical and Economic Review (ICER) report on insomnia therapies noted that orexin antagonists offer clinical advantages over off-label trazodone but at a cost-effectiveness ratio exceeding $150,000 per quality-adjusted life year at list price [21].

For patients switching from suvorexant to trazodone for cost reasons, the transition is clinically straightforward but should still be supervised. Patients who had failed trazodone previously and are now losing suvorexant access may be candidates for lemborexant (Dayvigo), another DORA with a shorter half-life and a different formulary position, or for referral to cognitive behavioral therapy for insomnia (CBT-I), which the AASM recommends as first-line treatment for chronic insomnia regardless of pharmacotherapy [5].

A Step-by-Step Switching Protocol

For trazodone to suvorexant: take last trazodone dose on night 1. Begin suvorexant 10 mg on night 2, taken within 30 minutes of bedtime with 7+ hours before the alarm. Reassess at 2 weeks. Increase to 20 mg only if 10 mg is insufficient and tolerated [4].

For suvorexant to trazodone: take last suvorexant dose on night 1. Skip medication on night 2 (washout). Begin trazodone 25 to 50 mg on night 3, taken 30 minutes before bed. Titrate by 25 mg every 3 to 5 nights as needed, with a ceiling of 100 mg for insomnia [1][6]. Monitor blood pressure in older adults during the first week [14].

Both directions: keep a sleep diary during the transition. If insomnia persists beyond 2 weeks after the switch, the prescriber should reassess for untreated sleep apnea, circadian rhythm disorder, or psychiatric comorbidity before adding a second agent [5]. The AASM advises against combining an orexin antagonist with a sedating antidepressant without a specific clinical rationale [5].